New hope for blood cancer patients: experimental drug MP0533 enters human trials

NCT ID NCT05673057

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tests a new drug called MP0533 in about 249 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The main goals are to find a safe dose and see if the drug can shrink or control the cancer. Participants must be at least 18 years old and have a life expectancy of 12 weeks or more.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AP-HP Hôpital Saint-Louis

    RECRUITING

    Paris, 75010, France

  • Amsterdam UMC - Locatie VUmc

    RECRUITING

    Amsterdam, Netherlands

  • CHU Bordeaux

    RECRUITING

    Bordeaux, France

  • Erasmus MC

    RECRUITING

    Rotterdam, Netherlands

  • Groningen UMC

    RECRUITING

    Groningen, Provincie Groningen, Netherlands

  • IUCT Oncopole

    RECRUITING

    Toulouse, France

  • Inselspital, Universitaetsspital Bern

    RECRUITING

    Bern, Canton of Bern, 3010, Switzerland

  • Universitaetsspital Zuerich

    RECRUITING

    Zurich, Canton of Zurich, 8006, Switzerland

  • Vilnius University Hospital Santaros Klinikos

    RECRUITING

    Vilnius, Lithuania

Conditions

Explore the condition pages connected to this study.